Year 2020 was an active year for the Court of Justice of the European Union (CJEU), the judiciary arm of the European Union (EU) that is supposed to avoid inconsistent interpretations of the EU law over the Member States. With two decisions rendered in April and July 2020, the CJEU made some progress in clarifying […]
8 January 2021
Learn more
The PACTE law (law n ° 2019-486 of May 22, 2019) relating to the growth and transformation of companies provided for several changes to patent law, aimed at enhancing the attractiveness and value of French industrial property titles. After extending the term of the Utility Certificate to 10 years, and creating a provisional patent application, […]
28 April 2020
Learn more
The high-stakes legal dispute on the CRISPR/Cas9 patented technology has at least the merit to have highlighted to the worldwide IP community how to secure a valid priority right in Europe. In a case that ended January 17, 2020, involving no less than 9 Opponents, the Board of Appeal of European Patent Office (EPO) confirmed […]
25 February 2020
Learn more
On January 10, 2020 was published Decree No. 2020-15 implementing the “PACTE” legislation (Action Plan for Business Growth and Transformation) which recasts and strengthens the French Utility Certificate, thus offering an appealing alternative to patents and a genuinely attractive tool to protect inventions having a rather short life cycle on the market. The prosecution of […]
11 February 2020
Learn more
The so-called “PACTE” bill, published in May 2019, brings substantial changes to the IP landscape in France. In-depth examination of French patent applications Until now, the French Patent Office (INPI) could not refuse a patent unless it lacked novelty. Examination of French patent applications filed on or after May 22, 2020, will now include a […]
21 June 2019
Learn more
On April 17, 2019, the European Parliament adopted an SPC manufacturing waiver for export and stockpiling Supplementary Protection Certificates (SPC) can extend the patent protection for medicaments by up to five years in the European Union. They had been introduced to compensate for the lengthy clinical development which must be completed prior to obtaining regulatory […]
21 April 2019
Learn more
If you would like more information, please do not hesitate to contact us. Please fill in the online form.
Paris
Cabinet Becker et Associés
25 rue Louis Le Grand
75002 Paris
Métro : Opéra
Parking : Opéra-Meyerbeer
+33 (0)1 53 43 85 00
Aix-en-Provence
Cabinet Becker et Associés
32 cours Mirabeau
13100 Aix-en-Provence
Parking : Mignet